Press Releases

As the number of COVID-19 cases and deaths continues to rise in most countries, Australian clinical-stage drug development company Noxopharm is pleased to announce treatment of the first patient with its lead pipeline candidate, Veyonda®, in the Company’s Phase 1 NOXCOVID-1 study. NOXCOVID-1 is looking at treating those COVID-19 patients hospitalized with moderate lung dysfunction requiring low oxygen support who are at risk of progressing rapidly into requiring intensive

Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced that it has presented patient-reported outcomes data from the Company’s pivotal Phase 3, open-label study “STOP 301” of INP104 (dihydroergotamine mesylate) or DHE using the company’s proprietary POD technology, for the treatmen

CellGenix GmbH, a pioneer for GMP grade reagents and a leading global supplier of high quality raw and ancillary materials for cell and gene therapies, announces the completion of the second phase of their facility expansion. CellGenix has reconstructed and expanded their production facility for cytokines and implemented a state-of-the art automated filling and freeze-drying line. By implementing an automated filling and freeze-drying line and increasing bulkware production footprin

The University of Tokyo and Eisai Co., Ltd. announced today a collaboration aiming for the development and drug discovery of targeted protein degradation technology has been created, with the establishment of a social cooperation program, "Protein Degradation Drug Discovery". The research time span will last five years from October 1, 2020 to September 30, 2025. The social cooperation program is established and operated based on funds of private organizations dedicated to

TreeFrog Therapeutics, a French biotech leveraging a unique cell manufacturing technology to advance a pipeline of cell therapies with mass-market potential, and Invetech, a global leader in the development and production of automated manufacturing solutions for cell and advanced therapies, today announced a strategic partnership to develop a GMP-compliant device for high-throughput stem cell encapsulation by the end of 2022. Since January 2019, TreeFrog Therapeutics has been collab

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced that the FDA has granted Orphan Drug Designation (“ODD”) and Rare Pediatric Disease Designation (“RPDD”) for its leading bispecific antibody program nivatrotamab for the treatment of neuroblastoma.

Tianda Pharmaceuticals Ltd is pleased to announce its wholly-owned subsidiary TDMall (Hong Kong) Ltd (TDMall HK) has acquired 50.1% equity interests in both Yeung & Young Medicare Centre Ltd (Yeung & Young) and Qi's Living Company Ltd (Qi's Living), for a total consideration of HK$25 million. Leaders in their markets in Hong Kong, Yeung & Young is principally engaged in the provision of high-end and modern TCM (traditional Chinese medicine) consultation and services, and Q

BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) protein therapeutics, and BeiGene, Ltd., a commercial-stage biotechnology company, today announced that the two companies have revised their previous global co-development and commercialization agreement for BioAtla’s investigational CAB CTLA-4 antibody, BA3071. The previous agreement from April 2019 now becomes a global licensing agreement for BA3071, which was

A2 Biotherapeutics (www.a2bio.com), a biotechnology company developing innovative cell therapies for solid tumor cancer patients, announced the closing of its $71.5M Series B financing. Proceeds will fund the advancement of its Tmod (T-cell module) platform and the clinical development and in-house manufacturing of its three near-term product candidates. Tmod-engineered T cells uniquely combine a potent activating mechanism to kill tumor cells with a blocking mechanism that protects normal ce

Terumo Blood and Cell Technologies today launches the Advanced Therapy Manufacturing and Innovation (ATMI) Grant 2020 for the Asia Pacific region. The ATMI Grant 2020 aims to accelerate advanced cell therapy manufacturing and development, with an award of up to USD 50,000 to principal investigators, scientists, researchers and clinicians exclusively from the Asia Pacific region to support the creative exploration of new and novel applications with the